Executive record

Paul Fonteyne

Director at Amylyx Pharmaceuticals, Inc.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:paul-fonteyneVersion: public-0As of: 2026-09-28

Not yet claimed12 published Claims7 sources
  • Director

Key Claims

Biography

Executive-in-Residence at Canaan Partners, a venture capital firm dedicated to early stage investing in healthcare and technology. Held numerous senior executive roles at Boehringer Ingelheim including Chairman and President/CEO of Boehringer Ingelheim USA. Extensive experience leading large commercial organizations in the pharmaceutical industry.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Board service

Boards

Apellis Pharmaceuticals, Inc.

Current

Claims

Conflicts and accountability

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

7 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. Amylyx Pharmaceuticals, Inc. director board source

    sec filing · Source published: Apr 23, 2026 · Retrieved: May 3, 2026

    Supports 4 claims
    • Board independence: Independent director · Claim reviewed: May 3, 2026
    • Board membership: Serves on the board of Amylyx Pharmaceuticals, Inc. · Claim reviewed: May 3, 2026
    • Board membership: Serves on the board of Apellis Pharmaceuticals, Inc. · Claim reviewed: May 3, 2026
    • Committee assignments: No committee assignment disclosed in the cited filing · Claim reviewed: May 3, 2026

  2. AMLX DEF 14A director slate

    sec filing · Source published: Apr 23, 2026 · Retrieved: Apr 24, 2026

    Supports 2 claims
    • Board role: Board role: Director · Claim reviewed: May 15, 2026
    • Committee assignments: Committee assignments: Compensation, Science/Innovation · Claim reviewed: Apr 24, 2026

  3. Open source

    sec proxy · Source published: Apr 23, 2026 · Retrieved: Apr 24, 2026

    Supports 1 claim
    • Professional Role: Director at Amylyx Pharmaceuticals, Inc. · Claim reviewed: May 15, 2026

  4. APLS DEF 14A director slate

    sec filing · Source published: Apr 23, 2025 · Retrieved: May 15, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Board role: Board role: Director · Claim reviewed: May 15, 2026
    • Committee assignments: Committee assignments: Audit, Compensation, Compliance · Claim reviewed: May 15, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 15, 2026

  5. Open source

    sec proxy · Source published: Apr 23, 2025 · Retrieved: Apr 24, 2026

    Supports 1 claim
    • Professional Role: Director at Apellis Pharmaceuticals, Inc. · Claim reviewed: May 15, 2026

  6. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Amylyx Pharmaceuticals, Inc. · Claim reviewed: May 3, 2026

  7. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Apellis Pharmaceuticals, Inc. · Claim reviewed: May 3, 2026